Low dose of Respiratory Syncytial virus prevents asthma development in a mouse model

CABALLERO M; ACOSTA PL; WIMMENAUER V; BRAHAMIAN JM; HIJANO DR; LAWRENCE A; MATEU, CG; POLACK FP

Nashville

Simposio; International Symposium on Respiratory Virus Pathogenesis and Immunity; 2013

Vanderbilt University

Upper respiratory tract infections (URTIs) during infancy have been shown to decrease the rates of pediatric asthma and AHR. Moreover, epidemiological data, studies in animal models support the hypothesis that a rationally designed live attenuated intranasal (IN) RSV vaccine (mimicking an RSV URTI) may contribute to modulate the development of immunity in the host and prevent asthma inception. Evidence suggest that RSV and its main protective antigen, the fusion (F) protein, can elicit a long-lived natural T regulatory (nTreg) lymphocyte response, presumably through Tlr2-dependent activation, negatively modulating asthma inception. The aim of this study is to determine whether immunization using RSV A2 or 171 low dose modulates the inception of allergic asthma.